Xenetic Biosciences develops XCART, a personalized CAR T cell platform that targets patient-specific tumor neoantigens. Their research focuses on oncology therapeutics, particularly cell-based treatments for B-cell lymphomas by targeting the B-cell receptor on tumor cells. Through collaboration agreements with several pharmaceutical companies, they are leveraging PolyXen, a proprietary drug delivery platform.